Cargando…
Long-term nifekalant use in a patient with dilated cardiomyopathy and recurrent ventricular tachycardia
The potential utility of nifekalant, a new Class III antiarrhythmic drug, to offer long-term protection against ventricular arrhythmia has been investigated in this case report. A 44-year-old male patient with dilated cardiomyopathy complicated with heart failure and persistent ventricular tachycard...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
SAGE Publications
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9620144/ https://www.ncbi.nlm.nih.gov/pubmed/36300319 http://dx.doi.org/10.1177/03000605221133704 |